β-glucan from Saccharomyces cerevisiae as a blood platelet antioxidant

Platelets

Volumn 21, Issue 6, 2010, Pages 451-459

  Saluk Juszczak, Joanna ^a   Krolewska, Karolina ^a   Wachowicz, Barbara ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

glucan; Antioxidant; Blood platelets; Oxidative stress; Platelet activation

Indexed keywords

3 NITROTYROSINE; BETA GLUCAN; PEROXYNITRITE;

ADULT; ANTICOAGULATION; ANTIOXIDANT ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADULT; ANTIOXIDANTS; BETA-GLUCANS; BLOOD PLATELETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; OXIDATIVE STRESS; PEROXYNITROUS ACID; PLATELET ACTIVATION; SACCHAROMYCES CEREVISIAE; YOUNG ADULT;

SACCHAROMYCES CEREVISIAE;

EID: 77955912796     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537101003780032     Document Type: Article

References (64)

1. Archibald MN, Israels SJ. Platelets and anti-platelets therapy. J Pharmacol Sci 2003;93:381-396.
2. Denese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 2005;25:103-121.
3. Jane E, Freedman MD. Molecular regulation of plateletdependent thrombosis. Circulation 2005;112:2725-2734.
4. Lundblad RL, White GC. The interaction of thrombin with blood platelets. Platelets 2005;16:373-382.
5. Spinelli SL, Brien JJ, Bancos S, Lehmann GM, Springer DL, Blumberg N, Francis CW, Taubman MD. The PPARPlatelet Connection: Modulators of inflammation and potential cardiovascular effects. PPAR Res 2008;1:1-16.
6. Gawaz M, Langer H, May E. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
7. Olas B, Wachowicz B. Role of reactive nitrogen species in blood platelet functions. Platelets 2007;18:555-565.
8. Krotz F, Sohn HY, Pohl U. Reactive oxygen species, players in the platelet game. Arterioscler Thromb Vasc Biol 2004;24: 1988-1996.
9. Wachowicz B, Olas B, Zbikowska HM, Buczyń ski A. Generation of reactive oxygen species in blond platelets. Platelets 2002;13:175-182.
10. John B, Hansch GM. Oxygen radical generation in human platelets: Dependence of 12-lipoxygenase activity and on the glutathione cycle. Int Arch Allergy Immunol 1990;93:73-79.
11. Olas B, Wachowicz B, Nowak P. Oxidative/nitrative modification of blood platelet proteins induced by thrombin in vitro. Thromb Res 2009;123:758-762.
12. Bloodsworth A, Valerine B, Freeman BA. Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. Arterioscler Thromb Vas Biol 2000;20:1707-1715.
13. Danese S, Motte Cd Cde L, Fiocchi MD. Platelets in inflammatory bowel disease: Clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004;99:938-945.
14. Matthias HF, Klinger WJ. Role of blood platelets in infection and inflammation. J Inter Cyt Res 2004;9:913-922.
15. Pitchford SC. Novel uses for anti-platelet agents as antiinflammatory drugs. Br J Pharmacol 2007;152:987-1002.
16. Saluk-Juszczak J. Znaczenie lipopolisachrydu bakteryjnego w procesie aktywacji plytek krwi. Post Biol Kom 2007;34:159-172.
17. Matthias HF. Platelets and inflammation. Anat Embryol 1997;196:1-11.
18. Rukhsana A, Edwin R, Kim M, Crow AR, Bang KWA. Platelet Toll-like receptor expression modulates lipopolysaccharyde- induced thrombocytopenia and tumor necrosis factor -α production in vivo. Blood 2006;107:637-641.
19. Xiao-Feng Y, Ying Y, Wang H. Vascular inflammation and atherogenesis are sctivated via receptors for PAMPs and suppressed by regulatory T cells. Drug Disco Today 2008;5:125-142.
20. Gawaz M, Langer H. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
21. Garry G, Susan J, Janet AM. Plant polyphenols in cancer and heart disease: Implications as nutritional antioxidants. Nutrition 2000;13:79-106.
22. Kogan G, Stasko A, Bauerova K, Palonka M. Antioxidant properties of yeast (1→3)-α-D-glucan studied by electron paramagnetic resonance spectroscopy and its activity in the adjuvant arthritis. Carbohyd Polym 2005;61:18-28.
23. Akramienie D, Anatolijus K, Didžiapetrienie J. Effects ofβ-glucans on the immune system. Medicina (Kaunas) 2007;43:597-606.
24. Olas B, Wachowicz B. Resveratrol and vitamin C as antioxidants in blood platelets. Thromb Res 2002;106:143-148.
25. Olas B, Saluk-Juszczak J, Wachowicz B. D-glucaro 1,4-lactone and resveratrol as antioxidants in blond platelets. Cell Biol Toxicol 2008;24:189-199.
26. Pryor W, Cueto R, Koppenol WH, Ngu-Achwemlein M, Squadrito GL, Uppu PL, Uppu RM. A practical method for preparing peroxynitrite solutions of low ionic strength and free of hydrogen peroxide. Free Rad Biol Med 1995;18:75-83.
27. Wachowicz B, Kustron J. Effect of cisplatin on lipid peroxidation in pig blood platelets. Cytobios 1992;70:41-47.
28. Walkowiak B, Michalak E, Koziolkiewicz W, Cierniewski CS. Rapid photometric metod for estimation of platelet count in blood plasama or platelet supension. Thromb Res 1985;56:763-766.
29. Walkowiak B. Adenine nucleotides in thrombocytes of birds. Cell Biochem Function 1984;2:167-170.
30. Buss H, Chan TP, Sluis KB, Winterbourn CC, Domigan NM. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;23:361-366.
31. Levine RL, Garland D, Oliver CN, Amici A, Climent I. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-476.
32. Khan J, Brennan DM, Bradley N, Gao B, Brukdorfer R, Jacobs M. 3-Nitrotyrosine in the proteins of human plasma determined by an Elisa method. J Biochem 1998;330:795-801.
33. Olas B, Nowak P, Kolodziejczyk J, Wachowicz B. The effects of antioxidants on peroxynitrite-induced changes in platelet proteins. Thromb Res 2004;113:399-406.
34. Sadula J, Kogan G, Kacurkova M, Machova E. Microbial (1→3)-α- D-glucans, their preparation, physico-chemical characterization and immunomodulatory activity. Carbohydrate Polymers 1999;38:247-253.
35. Gordon D, Brown G. Fungalβ-glucans and mammalian immunity. Immunity 2003;1:311-315.
36. Laroche C, Michaud P. New developments and prospective applications for β- (1,3) glucans. Recent Pat Biotechnol 2007;1:59-73.
37. Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP)β-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opinion Biol Ther 2005;5:691-702.
38. Hunter Jr KW, Gault RA, Berner MD. Preparation of microparticulate beta-glucan from Saccharomyces cerevisiae for use in immune potentiation. Lett Appl Microbiol 2002;35:267-271.
39. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996;98:50-61.
40. Patchen ML, MacVittie TJ. Stimulated hemopoiesis and enhanced survival following glucan treatment in sublethally and lethally irradiated mice. Int J Immunopharmacol 1985;7:923-932.
41. Ostroff GR, Ross GD, Jo Dockter Ross T. Patent application title: Methods of using beta glucan as a radioprotective agent. CONCORD, MA USA. IPC8 Class: AA61K31716FI; USPC Class: 514 54.
42. Volman JJ, Ramakers JD, Plat J. Dietary modulation of immune function byβ-glucans. Physiol Behavior 2008;94:276-284.
43. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 2004;173:797-806.
44. Cramer DE, Allendorf DJ, Baran JT, Hansen R, Marroquin J, Li B, Ratajczak J, Ratajczak MZ, Yan J. beta-Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood 2006;107:835-840.
45. Allendorf DJ, Ross GD, Ostrol GR. Oral WGP beta-glucan treatment accelerates myeloid recovery and survival after radiation exposure. Science & Technology for Reducing Biological Threats & Countering Terrorism 2003;104-111.
46. Elzey BD, Tian J, Jansen RJ, Swanson AK. Platelets mediated modulation of adapted immunity. A communication link between innate and adaptive immune compartments. Immunity 2003;19:9-19.
47. Kim GY, Choi GS, Lee SH, Park YM. Acidic polysaccharide isolated from Phellinus linteus enhances through the upregulation of nitric oxide and tumor necrosis factor-alpha from peritoneal macrophages. J Ethnophara 2004;95:69-76.
48. Shebuski JR, Kilgore SK. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002;3:729-735
49. Ari JF, Francisco AB. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev 2009;22:396-414.
50. Ferroni P, Basili S, Martini F, Vieri M. Soluble P-selectin as marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Thromb Haemost 2000;3:531-540.
51. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin J. Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Hematol 2001;115:566-601.
52. Fagerstam JP, Whiss PA, Strom M, Andersson A. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res 2000;49:466-472.
53. Ross R. Atheroschlerosis: An inflammatory disease. N Engl J Med 1999;340:115-126.
54. Saluk-Juszczak, Krolewska K, Wachowicz B. Response of blood platelets toβ-glucan from Saccharomyces cerevisiae. Platelets 2010;21:37-43.
55. Cheung P, Salas E, Schulz R, Radomski M. Nitric oxide and platelet function: Implications for neonatology. Semin Perinatol 2003;21:409-417.
56. Lufrano M, Balazy M. Interactions of peroxynitrite and other nitrating substances with human platelets: The role of glutatione and peroxynitrite permeability. Biochem Pharmacol 2003;65:515-523.
57. Mazzulli JR, Hodara R, Summer L, Ischiropoulos H. Oxidative stress and protein deposition diseases. Protein Rev 2007;24:123-133.
58. Reiter CD, Teng RJ, Beckman JS. Reaction of superoxide and nitric with peroxynitrite. J Biol Chem 2000;275:32460-32466.
59. Ischiropoulos H, Mehdi AM. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 1995;364:279-282.
60. Tsiapali E, Whaley S, Kalbfleisch J, Ensley HE. Glukan exhibit weak antioxidant activity, but stimulate macrophage free radical activity. Free Rad Biol Med 2001;30:393-402.
61. Babineau TJ, Hackford A, Kenler A, Bristrian B. A phase II imulticenter double-blind randomized placebo controlled study of three dosage of an immunomodulator (PPGglucan) in high-risk surgical patients. Arch Surg 1994;129: 1204-1210.
62. Karen LD, Martin E, Murad F. Novel effects of nitric oxide. Anuu Rev Pharmacol Toxicol 2001;41:203-236.
63. Butterfield AD, Tanea T, Perluigi M, Raffaella R, Jeffrey N. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007;1148:243-248.
64. Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharm Immunotoxic 2009;31: 13-29.